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Assessment  of  value  for money  of  new  drugs  is an important  part  in decision-making  about  the  price  and
use  of new  drugs.  The  high  prices  of  many  new  drugs  also means  that inappropriate  use  for  patients  who
gain  little  or  no  beneﬁt  from  the  treatment  creates  a high  “opportunity  cost”  in  terms  of  health  losses  for
other  patients,  for whom  the  resources  could  be better used.
Sales  of  cancer  drugs  in  Sweden  have  risen  sharply  over  the  past  decade,  but  the  growth  of  sales  has
slowed  in  recent  years.  There  are  signiﬁcant  variations  among  different  health  regions  in the use  of
cancer  drugs,  and  these  variations  have  increased  over the  past 5 years.  We  discuss  the issues involved  in
applying  the  principle  of  cost-effectiveness  with examples  from  breast  cancer  and  leukaemia.  The  debate
surrounding  the introduction  of  cancer  drugs  is  focused  on the  question  of  who  should  be  the leader  in
the  introduction  process.  Our  view  is  that in Sweden,  with a regionalised  health-care  system,  decisions
must  be made  where  patient  and  ﬁnancial  responsibility  rests,  on  the  county  councils.  However,  there  iseukaemia
olicy
a  need  for  leadership  at the  national  level  for assessment  and  follow-up.
Internationally, secret  (undisclosed)  rebates,  based  on what  is  often  a very  high  list price  for  the  drug,
are  common.  There  is no  tradition  of this  in  Sweden,  and  there  is  resistance  to this  type  of discounting  since
price  control  in  Sweden  should  be based  on public  prices.  However,  the  county  councils’  responsibility
for  the  introduction  of  new  cancer  drugs  allows  local  agreements  to  be  made,  in which  price  is  included
ving  
© 201 .as  one  component,  impro
ntroduction
Assessment of the value and cost-effectiveness of new drugs
lays an important part in decisions about the price and the use of
uch drugs. Equally important is the implementation of these deci-
ions in health care. Only when the drug is used properly is value
reated. A fundamental problem is that the value of the drug is not
ully known at the time the decision is made. The SNS (“Centre of
olicy Analysis, Stockholm Sweden”) research programme on the
alue of new drugs has presented a number of studies showing
hat the drug helped to create substantial value for health, care and
ociety in general (“Värdet av läkemedel”; The value of drugs. SNS
örlag 2013). Such studies provide important background informa-
ion, but give only partial guidance as to how we  can and should
anage the introduction and use of new drugs.
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Open access under CC BY-NC-ND laccess  for  patients  without  reducing  incentives  for  innovation.
4  The  Authors.  Published  by Elsevier  Ltd.  
The majority of new drugs, including those within the cancer
ﬁeld, have limited use and low sales. Only a small number of new
drugs have great value, and their sales ﬁnance the bulk of invest-
ment in research and development. The classiﬁcation of therapeutic
value made by the Haute Autorité de Santé (HAS) in France, for
example, shows that less than 10% of all new drugs end up in the
highest class of ﬁve (high therapeutic value) [1]. A study of drug
introductions in Sweden, using a three-level classiﬁcation, showed
that 14% ended up in the highest class (important medical contrib-
utions) [2]. Early access to these important drugs is therefore an
important goal. Increased requirements for documentation prior
to use, to ensure the efﬁcacy and cost-effectiveness of the drug,
may seem reasonable to reduce uncertainty. But reducing uncer-
tainty costs both time and money, and one cannot wait until one
knows everything. Decisions must be made with some uncertainty
about the value of a new drug.
In a much-quoted article, the economist Sam Peltzman analysed
drug approval decisions based on information on safety and efﬁ-
cacy. He pointed to the asymmetry of the consequences of early
approval or deferring the decision. Future adverse events may  lead
Open access under CC BY-NC-ND licenseto criticism of the authority for the decision to approve the drug.
However, a delayed introduction of a valuable drug rarely leads
to criticism just as harsh. The patients who  are missing out on the
positive effects of a potentially valuable treatment cannot similarly
icense.
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e identiﬁed. The “opportunity cost”, to use an economic term, is
ot possible to observe directly, and there is, as Peltzman pointed
ut, a risk that there will be a distortion of decisions as a result.
ystematic studies of the decisions and continuous assessment of
he consequences is the method he assigned to create a more opti-
al  balance, viewed from the perspective of society [3].
Peltzman’s analysis focused on the balance between efﬁcacy
nd side effects. In the 1960s, patients themselves paid almost the
ntire costs of medicines. Consideration of the cost was outside
ublic regulation. Today, public ﬁnancing is dominant, and the deci-
ion problem is a balance between public spending (subsidies) and
alue. Reimbursement decisions are also made with uncertainty,
ut the potential loss to society of a wrong positive decision lies
rimarily in the loss of money. It can be seen as trivial compared
o the loss of health if a new treatment that is potentially valuable
s not used. The pressure on approval will obviously be great from
otential patients who might beneﬁt from the new drug, especially
or severe diseases where potential side effects, relatively speaking,
re less of a problem. But as with balancing between safety and efﬁ-
acy, there is a hidden loss of health, namely health that could be
reated by using resources for more valuable purposes. The use of
ostly new cancer drugs on patients who gain little or no beneﬁt
rom the treatment will give rise to health losses in other areas
here resources could be better used. The use of different markers
or the identiﬁcation of patients who are candidates for treatment
ay reduce the risk of wrong decisions, but this cannot be imple-
ented without costs, and the decisions are often also complicated
y more sophisticated diagnostics.
The basis for the design of a rational policy is an understanding
f opportunity cost, regardless of whether this is directly visible or
ot. Systematic analysis of the consequences of the decisions, in
erms of costs and effects, is the main tool for assessing the balance
o aid decisions. We  give examples below of how the calculations
ave been used to guide decisions on the introduction of new cancer
rugs.
A fundamental problem with new cancer drugs is that they
re often introduced with relatively great uncertainty about their
ffects. The launch takes place with data only from patients with
isseminated disease and a short life expectancy, and in this popu-
ation the possibility of effectiveness weighs heavier than the risk
f side effects. Trials often use progression-free survival (PFS) as
 primary endpoint, which means that the effects on overall sur-
ival are uncertain, and in many cases cannot be measured because
f patients switching to the studied treatment (cross-over). This is
 particular problem for so-called targeted treatments. The basic
iological knowledge suggests that it is not reasonable just to
lock a single target. There are exceptions to this – for example,
reatment of CML  (chronic myelogenous leukaemia) and HER2-
ositive breast cancer – but these are not typical. A problem is
hat many of the new targeted drugs give a rapid and dramatic
umour response in some patients, but the tumour response is very
hort-lasting.
For the new immunological treatments the problems appear to
e the opposite: i.e., we see relatively modest tumour responses,
nd in some instances initial tumour progression followed by a long
eriod of tumour control, and possibly even cure in a proportion of
atients. The practical difﬁculties of making large and long-term
tudies often impede a full documentation of the relative efﬁcacy
nd safety of a drug before a decision on its use is made. It is an
mportant reason why new cancer drugs are introduced with great
ncertainty about long-term effects and value.
Thus there is a need for further systematic evaluation when a
rug is put on the market. The issue becomes: who  will pay for
his, especially when the prices are high and expenses can be con-
iderable for an uncertain outcome? The health-care system has the
esources and expertise for this, but decisions must be made thatancer Policy 2 (2014) 45–62
strike  a balance between different objectives when the resources
are limited.
One option would be to see follow-up studies as further
research, funded by special grants from the government as part
of the funding for medical research. This in turn requires decisions
about how large these funds should be and how they should be dis-
tributed, and when funding should be terminated. Another option
is to link the payment to the results achieved (known as “pay for
performance”), and that pharmaceutical companies and the health-
care system design the studies together and share the costs. A
problem with this model is that the outcome may  depend on a vari-
ety of factors, requiring a close and trusting cooperation between
pharmaceutical companies and health-care systems for it to work.
It is also important to remember that a drug does not have a
single value, but the value is related to which patients are treated.
The value can vary between different types of cancer, the stage
of the disease, and in what sequence it is given. Also the value,
measured as possible survival beneﬁt, varies with the characteris-
tics of the patient (such as age and co-morbidity). Since the value
varies, this also leads to problems of how to determine the price;
should an average price be calculated, or should there be differ-
ent prices for different uses? This leads to a discussion of whether
the payment should be tied to the drug itself, or whether it should
instead be linked to the patient being treated. In the latter case
the payment will be made for a service (such as hospitalisation or
outpatient treatment) rather than for a product. That creates oppor-
tunities for bundling, i.e. tying compensation to the estimated total
of all the costs associated with treatment, such as monitoring, treat-
ment of complications, etc. A new option is a “subscription fee”,
which means that a clinic pays a ﬂat fee and gets free access to
the drug for patients with the approved indication. This is simi-
lar to price–volume agreements, where there is a very low extra
payment if the agreed volume is exceeded.
Regardless of how “generous” the attitude of the payer decision-
maker is, there is a need to monitor what actually happens when
the drug is used in clinical practice. Sometimes it is not possible to
reproduce the effects observed in the clinical trials that formed the
basis for registration. This is because patients in a clinical study
differ in many ways from those treated in clinical practice. It is also
common that the number of cycles of treatment in clinical practice
is signiﬁcantly lower than that in the clinical study. This means
that the effectiveness of the drug is often lower than expected.
The opposite may  also occur, i.e., that the use in new populations,
or in a way  different from that in the clinical study, creates better
effects and greater value in clinical practice. For example, the use
of tamoxifen and trastuzumab in early breast cancer is more cost-
effective than using them in disseminated disease. It is therefore
important not to stop or delay the introduction of the drug even
though we  do not have full knowledge of the value of the treatment.
We also see examples of the effect in clinical practice being
greater than that observed in clinical studies. Such is the case for
imatinib in CML  and trastuzumab in the treatment of metastatic
breast cancer. The reason for this is that the clinical trials are fre-
quently reported with relatively short follow-up times, indicating
that the effect is underestimated in the proportion of patients
with good or very good clinical beneﬁt, who survive longer than
expected.
It is also important stop paying for the use of drugs if there is
no evidence that they create value. It is thus necessary to follow up
and verify early predictions. One way to generate the information
needed at a reasonable cost is to introduce speciﬁc payment models
for a limited introduction period. Payment during the introduction
period can be seen as an investment in the development of infor-
mation leading to better and safer decisions. This type of solution
has been named “coverage by evidence development”. Sometimes
it is also called a risk-sharing agreement, because in some cases
B. Jönsson, N. Wilking / Journal of Cancer Policy 2 (2014) 45–62 47
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he payment during the follow-up period is linked to a deﬁned
utcome, which is deﬁned in the reimbursement decision.
This  review of the introduction of cancer drugs in Sweden starts
ith a presentation of data on costs, including regional variations,
nd in the following section we compare the use of cancer drugs
n Sweden with that in other countries. Such descriptive data com-
rise important background information for policy, but will not in
hemselves provide any evidence on efﬁciency and equity in the
se of cancer drugs. This requires an analysis of value, and in the
ubsequent section we use tamoxifen, imatinib and trastuzumab
o illustrate the issues involved in assessing the value of a cancer
rug over its life cycle. This is followed by a review of how some
ancer drugs have been introduced on the Swedish market, focus-
ng on variations in use between the six health-care regions; each
esponsible for cancer care for a deﬁned population. The observed
ifferences in use have been discussed intensively, both from a
atient perspective of equal access to new treatments, and from
 cost and cost-effectiveness perspective. Are the observed differ-
nces evidence-based and in line with the stated objective in the
wedish health-care law that resources should also be allocated
ccording to their cost-effectiveness?
In  the ﬁnal section of the paper we set out some principles we
elieve must be observed in developing policies for optimal use of
edicines for cancer care – taking into account demands of patients
or equal access and the principle of the cost-effective use of health
are resources – and how these principles should be applied in the
wedish context.
ales  of cancer drugs in Sweden
Sales of cancer drugs in Sweden have risen sharply over the past
ecade. As shown in Fig. 1, the growth in sales has stagnated in
ecent years, which was predicted in the forecast we  made a few
ears ago [4]. There are several explanations for this development.
ome very important new drugs introduced 10–15 years ago (for
xample, rituximab, trastuzumab, imatinib and bortezomib) have,
fter a period of strong sales growth, reached a situation where
ost patients now receive them in treatment. Only a few drugs
f similar medical importance have been introduced during the
ast decade. Several new drugs have been added in areas where
here is competition, and the new drugs supplement and partially
eplace the ones already on the market. Impact on sales is thus
imited. The costs of cancer drugs have also been reduced due to8–2011. SEK per 100,000 inhabitants.
patent expirations, and the price reductions have been greater than
expected. Docetaxel and the so-called aromatase inhibitors (anas-
trozole, letrozole and exmestane) are examples in which prices
have fallen by over 90%. The high prices of several new cancer drugs
– up to 100,000 Euros per treated patient and year – combined with
limited survival gains have also delayed uptake and limited sales.
It should be kept in mind that the slowdown in sales growth in
recent years does not apply only to cancer drugs, but is observed
also for the pharmaceutical market as a whole.
All health-care regions (HCRs) have experienced large increases
in the costs of cancer drugs in the last 10 years (Fig. 2). However,
there is considerable variation between health regions in the use
of cancer drugs, especially during the last 5 years. These regional
variations are well known among leading oncologists, but they have
not brought about any major debate. The explanation may be that
the reasons for these regional variations and their consequences
have not been analysed in detail. There is no individual-level data
that would make it possible to study the causes of the difference in
total costs: for example indications or treatment patterns. It is also
impossible to determine whether the observed differences have
any effect on treatment outcome. Both over- and under-use may
occur, and the aggregate cost ﬁgures do not give any indication
of which one dominates. A more detailed analysis of the relation-
ship between costs and effectiveness is required to be able to make
policy-relevant conclusions.
There  are also signiﬁcant variations in the use of individual can-
cer drugs. For example, the use of bevacizumab varies by a factor
of four between the highest and lowest use in different HCRs. To
relate these differences solely to demographic or related factors do
not make sense. The most likely reason for the differences in how
bevacizumab is used is the existence of local therapy traditions in
different regions – what an economist would call “supply side fac-
tors”. These differences in usage are notable given that there is no
documentation supporting the cost-effectiveness of bevacizumab;
most recently, the National Institute for Health and Clinical Excel-
lence (NICE) in England found no support for the cost-effectiveness
of its use in the treatment of ovarian cancer [5]. They came to
the same conclusion as in previous evaluations of the use of beva-
cizumab in colon cancer and breast cancer. The new guideline by
the National Board for Health and Welfare in Sweden also gives low
priority for the use of bevacizumab in the treatment of colorectal
cancer, which is probably the indication with the most widespread
use. It is reasonable to be generous in the early assessments of
48 B. Jönsson, N. Wilking / Journal of Cancer Policy 2 (2014) 45–62
Fig. 2. Population-based sales of all cancer drugs in Sweden’s six health regions from 1998 to 2012. Use expressed in SEK per incident cancer case. Data for the western
health-care region are incomplete for 2012 and therefore are not included. Parts of the reporting for Stockholm are missing, but only for some of the sales in November and
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alue, but many years after the introduction of a drug one would
xpect that its use, outside research projects, would be focused
n indications where there is documented evidence for its cost-
ffectiveness.
A known pattern is that sales for a class of drugs over a cer-
ain period of time may  increase signiﬁcantly, and that the class
f drugs dominates the sales. Such was the case with drugs for
lcers, hypertension and dyslipidemia in the 1980s and 1990s, and
iologics for rheumatoid arthritis (RA) and multiple sclerosis (MS)
uring the 2000s. There are historically no cancer drugs among
he biggest sellers, but in the last 10 years there have been some
xamples: e.g., rituximab, trastuzumab, imatinib and bortezomib.
rastuzumab and rituximab were numbers 7 and 8 on the list of
he 15 best-selling drugs in Sweden in 2011. If we look at the sales
or the entire period 2000–2011 in the large US market, there is no
ancer drug on the list of the ten best-selling drugs.
On the Swedish market in 2011 there were just over 100 cancer
rugs with total sales of 2800 million SEK. As shown in Table 1,
he distribution of sales of drugs against cancer is very uneven. Of
he 20 top-selling drugs, the ﬁve top sellers account for 54% of total
ales. The 20 best-selling drugs account in turn for three quarters of
otal sales. Only a few drugs had sales of more than 100 million SEK
n 2011. On the contrary, most cancer drugs have very modest sales,
nd about 80 drugs comprise a quarter of the sales. Among these
re drugs that are widely used but cheap: e.g. tamoxifen (about 6
illion SEK). There are also expensive drugs – such as lapatinib –
hich are (as yet) limited to use in a small number of patients (11
illion SEK). Even with a focus on the newer cancer drugs there is
o change in the overall picture.
The conclusion is that sales for most cancer drugs are modest,
nd a few products dominate. The top ﬁve cancer drugs accounted
or 41% of total sales. This also includes all sales of rituximab, which
s also used for the treatment of rheumatoid arthritis (RA).
More  than 60 products have sales under 10 million SEK annu-
lly, and account for only 5% of the total sales of cancer drugs (see
ppendix).If we look at sales after the introduction year, products
ntroduced over the last 5 years (2007–2011) account for 14% of
otal sales, or a total of 384 million SEK. Lenalidomide is the drug
hat has the highest sales, at 110 million SEK in 2011. Cancer drugs Swedish cancer registry, http://www.socialstyrelsen.se/register/halsodataregister/
introduced  in the last 10 years (2002–2011) account for 36% of total
sales. The best sellers are bevacizumab (introduced 2005) at 147
million and bortezomib (2004) at 120 million SEK.
Sales of products introduced before 1997 – i.e. those which cur-
rently only exceptionally have patent protection – account for 255
million SEK of the total sales. The best-sellers are paclitaxel (1993,
1992) with 50 million, leuprorelin (1987, 1984) with 145 million,
doxorubicin (1978, 1971) with 50 million and methotrexate (1950)
to 59 million SEK (ﬁrst year refers to the ﬁrst sale in Sweden and
the second to the ﬁrst sale in the world). Note that methotrexate is
also used in RA.
Sales  of cancer drugs are thus dominated by a number of “best-
sellers” in the same way  as for the total pharmaceutical market.
It is these bestsellers that account for the bulk of the sales, pro-
ﬁts and revenue for ﬁnancing research and development. These are
also the drugs we  focus on when calculating the value of new drugs.
But it is important not to forget that drugs with small sales can still
be very valuable for certain patient groups. There are also drugs
that come late in the development in a speciﬁc therapeutic area
and have small incremental beneﬁts compared to those introduced
previously and already established; such drugs therefore have low
sales. It can still be proﬁtable for a single company to launch them,
but the importance for the patients overall is marginal, and it is
seldom that late introductions lead to price competition.
Sweden in an international context
Having described the introduction of cancer drugs in Sweden,
we will now describe how Sweden performs in an international
comparison.
As shown in Fig. 3, Sweden is in an intermediate position in the
use of new cancer drugs. France tops the use in Europe and is on a
par with the US. The high usage in France is partly explained by the
practice that most new cancer drugs are paid for separately, outside
of regular hospital budgets. The comparison can also be affected by
the system in France, with agreements on price and volume and
the repayments from companies not reported in the statistics. Use
of new cancer drugs in the UK is the lowest among the Western
European countries and can be explained mainly by a conservative
therapy tradition. In the Nordic countries, use in Sweden is now
B. Jönsson, N. Wilking / Journal of Cancer Policy 2 (2014) 45–62 49
Table  1
Twenty top-selling cancer drugs in Sweden 2009–2011.
Molecule/major indication Sales in million SEK Change Change % total sales of cancer
drugs  in 2011
2009 2010 2011 2009–2010 2010–2011
Trastuzumab/breast cancer 289 304 326 5% 7% 11.8
Rituximaba/lymphoma 231 267 309 16% 16% 11.2
Imatinib/CML 204 213 208 5% −2% 7.8
Bevacizumab/CRC 107 130 147 21% 13% 5.3
Leuprorelin/prostate cancer 156 151 145 −3% −4% 5.2
Bortezomib/myeloma 81 96 129 18% 35% 4.7
Lenalidomide/myeloma 58 75 110 29% 46% 4.0
Pemetrexed/lung cancer 78 83 97 7% 16% 3.5
Sunitinib/RCC 55 61 65 11% 7% 2.3
Temozolomide/brain tumour 75 72 64 −3% −11% 2.3
Goserelin/prostate cancer 71 65 61 −8% −7% 2.2
Methotrexate/breast cancer 51 56 59 10% 5% 2.1
Erlotinib/lung cancer 47 50 51 6% 2% 1.8
Doxorubicin/lymphoma 46 53 50 15% −5% 1.8
Paclitaxel/ovarian cancer 46 46 50 1% 7% 1.8
Cetuximab/CRC 55 57 49 4% −14% 1.8
Capecitabin/CRC 44 46 47 6% 1% 1.7
Buserelin/prostate cancer 37 42 46 13% 8% 1.7
Docetaxel/breast cancer 181 169 43 −7% −75% 1.6
Dasatinib/CML 31 36 42 17% 15% 1.5
Source: Drug Statistics, Sweden.
CML, chronic myeloid leukaemia; CRC, colorectal cancer; RCC, renal-cell carcinoma.
a It should be noted that the increase in use of rituximab to a large extent probably can be attributed to use in rheumatology.
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ower than that in Denmark and at about the same level as that in
inland, but still higher than that in Norway.
Figs. 4 and 5 show an international comparison of the use of
wo important new drugs, trastuzumab and imatinib, measured in
g/case of breast cancer and leukaemia, respectively, in a selection
f countries. This measure shows the proportion of patients who
re treated, and eliminates the impact of potential differences in
rices.
Most notable are the high sales in France. This is probably due
ainly to trastuzumab, paid for separately outside the hospital’s
udget, but may  also be because of increased volumes due to dis-
ounts as a result of agreements on price and volume. The use in
weden and the UK is rather similar. The sales in eastern European new) in selected European countries for the years 1999–2009. Euro per 10000 of
countries  are much lower, and there are also large differences
between these countries.
For  imatinib, the differences between the European countries
are smaller than for trastuzumab. The Swedish sales are slightly
below average for the Western European countries. Remarkably,
England and Sweden are relatively close to each other in the use of
imatinib as well as trastuzumab. The use of cancer drugs in England
is generally lower than that in Sweden. This could be interpreted by
the fact that Sweden follows the NICE recommendations, at least
for cancer drugs with proven cost-effectiveness.
A more comprehensive review of the introduction and use of
new cancer drugs conﬁrm the impression that Sweden does not
stand out in an international comparison [6]. However, there are
50 B. Jönsson, N. Wilking / Journal of Cancer Policy 2 (2014) 45–62
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o reliable international data from the last 5 years which, in light
f the sharp decline in sales of cancer drugs in Sweden, might give
 different picture.
he  value of innovative cancer medicines
Decisions on the introduction and use of new cancer drugs
hould be based on knowledge (evidence) of their value. We  have
reviously discussed the difﬁculties in making an assessment of
alue early in the development of a new cancer drug. In this sec-
ion we describe in detail the methods and data used, based on a
ew examples.
The important principle is that the value is derived from the
rug’s overall effect on the patient. What we want to focus on is
he necessity – and the difﬁculty in the early stages – of having evi-
ence of these effects on the patient. How great is the increase in
urvival? How is the quality of life affected? How much does the
reatment cost change? How is the possibility of working and per-
orming other activities affected? Before we can have a meaningfulweden, Czech Republic and Hungary, and the average in a section of the Western
w.iarc.fr/.
discussion  on how these effects should be assessed, and how the
appraisal of the different effects is made, we must know the mag-
nitude of the different relevant effects observed.
Tamoxifen in breast cancer
In  a calculation of the return on investment in health care in the
United States for the period 1980–2000, breast cancer is identiﬁed
as an area of high return; this is especially true of tamoxifen in early
breast cancer to prevent recurrence of the disease [7]. The return
is calculated as the number of QALYs (quality-adjusted life years)
gained multiplied by a ﬁxed price based on US studies of willingness
to pay for a QALY. The high return from tamoxifen therapy for breast
cancer is due to low cost combined with good effect. The patent for
tamoxifen expired during this period, and controlled studies have
conﬁrmed the increase in survival from the treatment. It may be
added that in the 1970s and early 1980s it was not proven that
tamoxifen had an effect on survival, and the high cost of the drug
was questioned. The pivotal study showing improved survival in
B. Jönsson, N. Wilking / Journal of C
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he adjuvant treatment was ﬁrst published in 1988; 13 years after
hat tamoxifen ﬁrst came onto the market. An important factor in
his work was meta-analysis conducted by the EBCTCG (Early Breast
ancer Trialists’ Collaborative Group) based on data from more than
00,000 women [8].
The  social value of tamoxifen in Sweden for the period
979–2004 was estimated at over 25 billion SEK ([9,10], p. 20).
uch of the use and beneﬁts came after the patent expired, and
amoxifen is still used – almost 40 years after its introduction – at a
ery low price (Fig. 6). The Swedish study conﬁrms the results of the
forementioned US study, but also provides important additional
nformation. First, that the gain in survival and quality-adjusted
urvival was three times higher in the adjuvant treatment than
ith disseminated disease. Second, it took a long time to arrive
t the optimal duration of adjuvant treatment, depending on both
he time it took to document the medical effects and that the price
or the 5-year treatment was initially perceived as high. It is inter-
sting that now, after so many years, there are discussions about 10
ears of treatment, instead of 5, on the basis of new studies. There
s also new evidence on the value of tamoxifen for primary preven-
ion of breast cancer, which may  provide even more value in the
uture [11,12].
Third, the example shows that it took a relatively long time after
atent expiry before the price was reduced to the current level.
inally we note that, even taking inﬂation (changes in the con-
umer price index) into account, the price for tamoxifen, when it
as introduced, was signiﬁcantly lower than the prices for today’s
ew cancer drugs.
matinib  for the treatment of chronic myeloid leukaemia
CML)/gastrointestinal stromal tumour (GIST)
Imatinib showed an overall survival beneﬁt in CML  in early
linical trials. As the follow-up period was limited, the estimated
umber of life years gained (LYGs) per patient was associated with
reat uncertainty. In a study of imatinib compared with interferon,
stimated survival time was 15.3 and 9 years respectively, a sur-
ival gain of more than 6 years for those treated with imatinib
13]. The annual cost of treatment with imatinib is approximately
00,000 SEK, and for an individual patient treatment for many years
mounts to several million SEK. The large survival beneﬁt provides a
easonable cost-effectiveness, despite the high cost. Over time, the
alculations have been revised and the results show that the sur-
ival beneﬁts as well as the costs were underestimated in the early
alculations. The number of LYGs is estimated at 10.0 and the num-
er of QALYs gained at 8.9, resulting in a cost per QALY of around
50,000 SEK (50,000 USD), close to earlier estimates. Costs haveancer Policy 2 (2014) 45–62 51
also  increased compared to the previous calculations, as a result of
longer treatment duration and higher price [14].
The research and development of imatinib is an interesting story
in many respects, not least because it also illustrates some impor-
tant moral and economic issues. The price of imatinib was  30,000
USD per year of treatment, and a programme was introduced to
help patients who  could not pay [15]. But over time, the price has
increased, and the cost of treatment has increased to 90,000 USD
[16]. The long survival time means that the costs of health care rise
year by year as more and more patients receive treatment.
Two  new drugs (dasatinib and nilotinib) that complement and
substitute for imatinib were introduced in 2006 and 2007 respec-
tively, which can further improve treatment outcome but at a
higher cost. In 2012 the Food and Drug Administration (FDA)
approved another three drugs for the treatment of CML: bosu-
tinib, ponatinib and omacetaxine. The price for these is in the order
of 100,000 USD per year. When the patent for imatinib expires
in 2015 the price will drop signiﬁcantly, while medicinal value
for patients continues. But the economic issues will persist. The
cost difference between different drugs for CML will be even more
pronounced when the patent for imatinib expires. The new drugs
provide opportunities to treat patients who  no longer respond to
previous treatments, and also provide opportunities to eventually
ﬁnd the optimal treatment for each patient. However, many new
studies are needed to come up with the necessary evidence, and
the ﬁnancial implications must be considered.
Imatinib was  introduced for a new indication, GIST, which
requires new calculations to relate costs to beneﬁts in terms of LYGs
and QALYs [17]. This once again shows that a drug does not have
just a single value, and that new evidence must be developed for
each indication.
While early estimates of the cost-effectiveness of imatinib gave
very accurate predictions, the later developments – with further
introductions of drugs for the same indication – show that follow-
up studies are essential to validate previous assumptions and to
adjust treatment as new alternatives are added.
Trastuzumab in the treatment of HER2-positive breast cancer
Trastuzumab was  introduced in Sweden in 2000 for the treat-
ment of metastatic breast cancer. In 2005, trastuzumab was sold
for about 92 million SEK in Sweden, and in 2011 sales amounted
to 326 million SEK. The increase in sales is due mainly to the data
presented in 2005 when trastuzumab is used as adjuvant therapy
for early disease.
Cost-effectiveness depends on how patients are identiﬁed for
treatment, because the beneﬁts of treatment depend on whether
the patient’s tumour demonstrates an increase in a speciﬁc cell
receptor (HER2) or ampliﬁcation of the gene for the receptor. The
choice of testing strategy becomes an economic issue in itself. The
two tests used to determine the HER2 status, IHC (immunohisto-
chemistry) and FISH (ﬂuorescence in situ hybridisation), cost about
2000 and 5000 SEK respectively. Since the cost of trastuzumab is
approximately SEK 330,000 for a year of treatment, the possibility
of identifying the 15–25% of patients who might beneﬁt is impor-
tant also for economic reasons. The ability to identify patients who
may  beneﬁt from a treatment is always an asset, but how the test
should be used in an optimal manner must be assessed case by case
and depends, among other things, on the cost of the test and the
proportion of patients expected to have disease. The choice of test-
ing strategy becomes part of the larger issue: how to optimise the
treatment regarding cost and efﬁcacy [18]?In a Swedish study, the cost-effectiveness of trastuzumab in the
treatment of metastatic breast cancer was  estimated at 485,000
SEK per QALY gained using a FISH-based test strategy. It is a rela-
tively high ratio, but it is within what would normally be considered
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 cost-effective treatment [19,20]. Cost-effectiveness of adjuvant
rastuzumab for Sweden is estimated at 335,000 SEK (36,000 USD)
er QALY gained. Cost-effectiveness is therefore better for the adju-
ant treatment than for treatment of metastatic disease. This is not
ncommon, and results of analysis of price in relation to the beneﬁt
n the treatment of metastatic disease (485,000 SEK) underesti-
ates the beneﬁts of potentially curative treatment [19,20].
A  shift towards more “individualised treatment” will further
ncrease the complexity of the evaluations because the number of
reatment strategies will increase. Every indication must be studied
eparately for beneﬁts and costs, as it involves additional treat-
ent strategies. Treatment with trastuzumab in early breast cancer
ust be studied separately, but will also have an impact on the
osts and beneﬁts for the treatment of metastatic disease because
any patients have already been treated once before. Adjuvant
herapy also means that many more patients will be treated (1000
atients are considered for therapy, compared with 300 patients
ith metastatic disease), which increases the burden on the health-
are budget. It is therefore common that adjuvant treatment is
ubjected to more thorough economic analysis.
It is also important to ensure cost-effectiveness in the longer
erm. Trastuzumab, like tamoxifen, will probably be a valuable
rug long after the patent has expired. If we assume that the
rice is halved after patent expiry, the cost/effectiveness ratio
ill be reduced by 50%. The net value to society of the drug is
hus increased, while the value of the company that developed it
ecreases as sales are reduced.
he introduction of innovative cancer medicines in Sweden
 some examples
rastuzumab
The  introduction of trastuzumab varied among HCRs in Sweden.
his was probably related both to the high cost of the drug and to
ifferent interpretations of the clinical effectiveness of trastuzumab
n metastatic breast cancer. In 2005, data on a 1-year adjuvant use of
rastuzumab was presented. The studies demonstrated an impres-
ive reduction in disease relapse. This led to a rapid increase in
he use of trastuzumab in all HCRs. This increase started already
n 2005, i.e. before trastuzumab was approved for this indicationin Sweden 2000–2011. Use expressed in SEK per incident cancer case.
 Swedish cancer registry, http://www.socialstyrelsen.se/register/halsodataregister/
(April  2006). However, relatively large differences in use persisted.
The introduction of trastuzumab in Sweden has been at a medium
level, seen in relation to the rest of Western Europe. But the differ-
ences within Sweden are at least as big as the difference between
Sweden and France (Fig. 7).
Imatinib
The introduction of imatinib was more uniform in Sweden, as
was observed in the comparison between different EU countries.
This was probably due to the relatively few patients (<100 new
cases/year) being treated by a limited number of specialists, com-
bined with generally accepted evidence on the effectiveness and
cost-effectiveness of the drug (Fig. 8).
Drugs used in renal-cell carcinoma
Renal-cell carcinoma (RCC) accounts for about 2–3% of the
cancer incidence in Sweden, and approximately 1100 patients
are diagnosed per year. Because survival in metastatic disease is
low, the prevalence remains low. RCC is the most deadly form
of urological cancer, and the sixth leading cause of death from
cancer in Sweden. Chemotherapy has had limited effect, and the
only treatment – with a minor effect – has been cytokine-based
immunotherapy with interferon or interleukin; the response rate
is modest (about 15%) and toxicity is high. The introduction of the
ﬁrst new, targeted, tyrosine kinase inhibitors (TKIs) – sunitinib and
sorafenib in 2006 – resulted in new treatment opportunities and the
potential for improved outcome. Later several new targeted treat-
ments have been approved in RCCs, such as the small molecules
pazopanib and bevacizumab and the mTOR inhibitors temsirolimus
and everolimus.
The  approvals on drugs in RCC have been almost exclusively
based on data related to progression-free survival, and only one
study has shown an effect on overall survival.
In a recently published Swedish study, which looked for
improvement in survival in patient registry data, the authors noted
an increased survival in kidney cancer in Sweden, but it is difﬁ-
cult to tell how much of this improvement can be attributed to the
introduction of new drugs in the area [21]. One possible explanation
for the lack of a signiﬁcant effect on survival may be that virtually
B. Jönsson, N. Wilking / Journal of Cancer Policy 2 (2014) 45–62 53
egions
a
s
p
w
c
u
f
b
a
p
T
d
B
c
t
m
d
a
C
m
i
s
F
r
n
t
d
h
c
k
b
o
w
t
dFig. 8. Population-based sales of imatinib in the six health-care r
Source:  Pharmacy Statistics, Cancer.
ll drugs were approved on the basis of gains in progression-free
urvival. In order to study the long-term effect on survival from
rogress in treatment, one needs systematic data from patients
ith disseminated disease, something that is lacking today.
Thus,  there are at present six new drugs used primarily in renal
ancer (bevacizumab also has this indication, but has had limited
ptake in RCC in Sweden). Several of these new drugs are also used
or other indications such as liver cancer, neuroendocrine tumours,
reast cancer and sarcoma. Kidney cancer is a research-intensive
rea, which is why some of the variation is probably due to many
atients being in clinical trials and therefore receiving free drugs.
he use of ﬁve RCC drugs is given in Fig. 9. Total sales for these ﬁve
rugs amounted to about 130 million SEK in 2011.
evacizumab, cetuximab and panitumumab in the treatment of
olorectal cancer
Until  the late 1980s the general opinion was that medical
reatment of colorectal cancer (CRC) had little or no effect. Improve-
ents in survival data were due mainly to the development of
iagnostic and surgical techniques. After the publication of data on
djuvant therapy with 5-ﬂuorouracil (5-FU) in the 1980s and 1990s,
RC developed into an area where the use of drugs increased dra-
atically. In the 1990s it was shown that irinotecan and oxaliplatin,
n addition to 5-FU, have an effect on CRC. These drugs are still the
tandard treatment for both early and advanced CRC. Adjuvant 5-
U (now also an oral treatment) in combination with oxaliplatin
esults in improved survival for stage III patients (spread to lymph
odes), while the value for stage II patients (tumour grows through
he intestinal wall) is uncertain. For stage I patients (only local
isease) surgery remains the standard treatment.
Biological treatment with bevacizumab (angiogenesis inhibitor)
as been approved as ﬁrst-line therapy for advanced CRC. Beva-
izumab now has a number of other indications (breast, lung and
idney cancers), but the breast cancer indication in particular has
een discussed and the FDA in the USA has withdrawn its approval.
A recent development in CRC is the identiﬁcation of a subgroup
f patients with a particular non-mutated gene expression called
ild-type KRAS (approximately 50%). Patients in this subgroup are
he only ones who will beneﬁt from a new class of drugs – the epi-
ermal growth factor receptor (EGFR) inhibitors. At present there in Sweden 2011. Use expressed in SEK per incident cancer case.
are  two drugs, cetuximab and panitumumab, approved for non-
mutant KRAS patients.
All  of these drugs will prolong progression-free survival in CRC,
but have only modest effects on overall survival and in some spe-
cial situations. None of the drugs have increased the survival in the
adjuvant situation, and their impact on survival in the metastatic
situation is limited. In the guidelines of the Swedish Board of Health
and Welfare these antibodies are given low priority. The excep-
tion is the use of EGFR antibodies in potentially surgically treatable
disease spread only to the liver or lung.
There are major variations in the use of bevacizumab in Sweden
(Fig. 10). It is notable that in some regions (Stockholm and South-
ern) its use was  signiﬁcantly decreased in 2012. Data for Stockholm
for November–December 2012 are incomplete.
Examples of drugs introduced 2011–2012
The Swedish Pharmaceutical and Dental Reimbursement Board
(TLV), as well as the Swedish Association of Local Authorities and
Regions (SKL), have intensiﬁed their role in the assessment of new
cancer drugs during recent years.
Ipilimumab, a new drug and a new immunological treatment
principle for the treatment of disseminated melanoma disease
(Fig. 11), was approved in June 2011. Treatment with ipilimumab
consists of four injections, and the list price is close to 800,000 SEK
per treated patient. The SKL in collaboration with the Regional Can-
cer Centre (RCC) took on the role of negotiating at national level. It
was not until the end of June 2012 that the SKL group for new drugs
(NLT) reached an agreement on a national discount. From a patient
perspective, obviously this delay of 1 year is not acceptable.
Vemurafenib, the other new drug for metastatic melanoma
(Fig. 11), was  approved at the end of 2011 by EMA  (2011) and
reached the market in March 2012. The cost of the drug is high
– around 80,000 SEK/month – and survival impact is limited (3.9
months). The TLV’s decision came in October 2012 and it found that
the drug had a QALY cost that was  above the TLV limit. Vemurafenib
was introduced in the EU with a price 35–36% above the list price in
the United States, which is surprising because prices in the EU tend
to be lower than in the US. NLT has now come to a rebate agreement.
The problem with a solution between SKL/NLT/RCC in collabora-
tion and respective pharmaceutical companies is that some central
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Fig. 9. The use of ﬁve kidney cancer drugs in the six health-care regions in Sweden 2011. Use expressed in SEK per incident cancer case.
Source: Pharmacy Statistics, http://www.ehalsomyndigheten.se/lakemedelsstatistik/ and Swedish cancer registry, http://www.socialstyrelsen.se/register/halsodataregister/
cancerregistret/inenglish.
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udget funds are not linked to the introduction. Therefore the com-
anies must, as before, proceed with negotiations at the local level.
In the prostate cancer ﬁeld, two new drugs were introduced in
011 (Fig. 12). First, abiraterone, a new hormonally active drug, was
ntroduced for the treatment of patients with metastatic prostate
ancer refractory to hormonal treatment; second, cabazitaxel, a
ew chemotherapy agent, was approved for the same patient pop-
lation in early 2012. TLV evaluated abiraterone in June 2012 and
ound that the drug was not cost-effective. The TLV has also com-
ented on cabazitaxel within the context of an ongoing clinical
rug project and concluded that cabazitaxel was not cost-effective.
he rejection of abiraterone by the TLV has been followed by nego-
iation between NLT and the company in December 2012. They
eached an agreement, which provides a limited discount – how-
ver, in our opinion, far from the NICE level (see below).
It  is interesting to compare the “undisclosed” discounts in
weden on abiraterone, ipilimumab and vemurafenib with what
ICE accomplished in England. Discount levels in England appear toden 2005–2012. Use expressed in SEK per incident cancer case.
 Swedish cancer registry, http://www.socialstyrelsen.se/register/halsodataregister/
be far higher than those achieved in Sweden by the SKL/NLT/RCC in
collaboration. One reason for this may  of course be that the Swedish
market is much smaller, and that a central agreement does not guar-
antee a regional/local use. One may  also question whether the SKL
has taken on a mandate that should reasonably be taken on by a gov-
ernmental organisation (if one wants a national solution, within the
national budget) or regional/local (where the budget is today). One
should also expect similar discount terms for England (Table 2).
Discussion  and conclusions
What  is unique about cancer?Cancer  comprises many different diseases that represent very
different challenges in terms of diagnosis, treatment and follow-
up. Many drugs used in the treatment of cancers are approved
with limited data on the impact on survival. This means that
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Fig. 11. Use of new melanoma drugs in the six health-care regions in Sweden 2011–2012. Use expressed in SEK per melanoma mortality.
Source: Pharmacy Statistics, http://www.ehalsomyndigheten.se/lakemedelsstatistik/. Cause of death registry, http://www.socialstyrelsen.se/english.
Fig. 12. The use of new prostate cancer drugs in the six health-care regions in Sweden 2011–2012. Use expressed in SEK per prostate cancer mortality.
Source:  Pharmacy Statistics, http://www.ehalsomyndigheten.se/lakemedelsstatistik/ and Cause of death registry, http://www.socialstyrelsen.se/english.
Table 2
Cost  per quality-adjusted life year (QALY) estimates for selected newly introduced cancer drugs.
TLV (thousand SEK) NICE (thousand SEK)
Abiraterone - prostate cancer 1300 490a
Bevacizumab – ovarian cancer Not evaluated 1357–1707
Ipilimumab – malignant melanoma 1080 447a
a
C sed o
p
i
i
a
a
n
a
wVemurafenib – malignant melanoma 1050 
alculations from the National Institute for Health and Clinical Excellence (NICE) ba
a In several cases.
ost-approval follow-up and collection of “real-life” data are key
n evaluating cancer drugs. In addition, cancer drugs are often used
n combination or in sequence with each other, a practice which
lso needs to be evaluated in clinical practice. It is the total impact
nd cost of various treatment strategies that the health-care system
eeds information on to provide the best possible care.
A  new aspect of cancer treatment is the high prices of several
nticancer drugs introduced in the last decade. It commonly comes
ith a price tag of 60,000–70,000 SEK per treatment month, or466–549
n undisclosed discounts. Calculated on 1 GBP = 10.60 kronor.
about  800,000 SEK per year. This high price can be explained partly
by the high cost of developing new cancer drugs, but is nevertheless
a problem for the health service and the community. The pharma-
ceutical cost of treating a patient may  be equal to the cost of a
doctor’s salary for a year. This means that there is an alternative
use of resources, within both cancer care and other areas of health
care. Health care is therefore forced to strike a balance between
how much should be spent on a new cancer drug in relation to
other health-care interventions. These choices are not easy, but
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nfortunately they are necessary. Because they are so important,
hey must be taken transparently and based on rational criteria,
ith the aim of creating the most efﬁcient and equitable care pos-
ible.
The problem of prices is different from a societal perspective.
he prices do not reﬂect the costs of producing and using the drugs.
f one makes a comparison with the prices for going over the Ore-
und Bridge (the bridge between Sweden and Denmark), the cost
f one passage has no relation to the cost of the passage itself. The
ridge is there, and the additional cost of one or several thousands
f vehicles passing will be just about the same. The prices for new
ancer drugs represent mainly a reward for the investments the
ompany have made in developing the drug, and a compensation
or the costs of producing the substance. Similarly, ﬁnancial charges
or crossing the Oresund Bridge almost exclusively relates to the
osts associated with building the bridge. When the patent on a
rug expires, it is not uncommon for the price fall by over 90%.
rom a societal perspective, it is then optimal to treat all patients
ho might beneﬁt from the drug, regardless of the price. For the
harmaceutical company it is not primarily the price but the total
evenues that are vital to the proﬁtability of developing new cancer
rugs.
Sorafenib for the treatment of advanced renal-cell cancer may
llustrate the problem. The cost of treatment with the drug
pproved in Sweden (is about 35,000 SEK per month). However,
orafenib is also available in a generic form, made in India, at a
rice of approximately SEK 1200 per month [22]. In order to create
ncentives for innovation, it is necessary to pay the company that
eveloped the drug more than just manufacturing costs until the
atent expires in 2020. The question to be answered is: how much?
till, at the same time it is important that payment is made in a way
o as not to hinder those patients who might beneﬁt from the drug
rom getting it. It would be of mutual interest to have an agreement
etween the company and the health-care provider giving higher
otal revenues, although the price per treated patient will be lower.
Another question is: how should the products of the same “class”
e used and paid for? The principle today is that they are usu-
lly introduced at the same price as the ﬁrst drugs in that class
aunched in the market. New products will lead to some increase
n the overall market, but the main effect is that they share the
arket.
ifferent approaches to handling the high international prices of
ancer drugs
International prices are determined by the ability and willing-
ess to pay for cancer drugs by private insurers in the US. However,
hose prices are not directly relevant for Sweden, since the actual
rices paid by private and public health insurers are lower because
f rebates and co-payments. In the US it is also common for compa-
ies to pay at least part of the co-payments that patients have to pay
o get access to the drug. These can be up to 20% of the price, which
eans up to 12,000–15,000 USD per year. Cancer is unfortunately
 common cause of personal bankruptcy in the US [23].
Cancer  drugs are also commonly discounted to hospitals and
reating oncologists, which means that the price paid is lower and
aries between different customers. The system in the US – where
ncologists purchase and administer the drug, and are then reim-
ursed by the insurance company – has been questioned [24]. In an
rticle in Health Affairs, the head of cancer care within the United
ealthcare, Minnesota, argues for a compensation system based on
erformance [25].It  is thus not meaningful to compare drug prices in the US
ith drug prices in Sweden where, until recently, no discounts
ere given and there are no co-payments. The level of health-care
xpenditures – and salaries for oncologists and prices for otherancer Policy 2 (2014) 45–62
health-care  resources – are also much lower. It is therefore desir-
able to develop a new compensation system that encourages better
use of medicines, leading to more cost-effective care.
England, like Sweden, has low or no co-payments for cancer
drugs. But increasingly, new cancer drugs are introduced in the UK
with a market access agreement, which in essence is a rebate on
the price. The price adjustment is done by negotiations between
the companies and NICE, which evaluates and advises on the use
of such new cancer drugs. The basis for the agreements is an esti-
mate of the drug’s cost-effectiveness, expressed as cost per QALY
gained. This ratio should not be higher than 20,000–30,000 GBP,
or in exceptional cases 50,000 GBP per QALY. If the cost per QALY
is higher, NICE usually recommends that the drug should not be
used. This was the case in a recent evaluation of bevacizumab in the
treatment of ovarian cancer [5]. Similarly, NICE ﬁrst recommended
against the use of abiraterone for the treatment of prostate can-
cer in the NHS, but the recommendation was later changed on the
basis of an agreement reached on an undisclosed discount on the
list price.
In  the US, as well as in England, the ﬁnal prices paid are not
ofﬁcial, although it is possible to make an estimate of the size of
the discount. Therefore, we  see a movement where the price for
new cancer drugs will be subject to national/local agreements, and
that the previous model with a deﬁned “global” price is about to
be abandoned. The wide variations in income level between differ-
ent countries make it difﬁcult to maintain a uniform global price,
supporting a development in this direction.
What can and should we do in Sweden?
The development of new cancer drugs is a process in which
Sweden has little inﬂuence. The drugs come to market through
approval by the European Medicines Agency and Sweden can only
decide which patients they should be used and paid for. There are
currently two  separate ways for patients to get access to new cancer
drugs in the Swedish public health-care system.
One route is through the decision by the TLV that they should be
included in the beneﬁt scheme for prescribed medicines. Cancer is
a serious disease, and available treatments often have serious side
effects and limited effectiveness. Access to new cancer medicines
may be important, not to say vital, for the patients. The two overrid-
ing criteria for reimbursement are equal access to health care and
that patients with the greatest need should have priority. Accord-
ing to these criteria, most cancer medicines will be reimbursed.
The third criterion, cost-effectiveness, is more problematic. Only in
cases where the new treatment has a similar or lower price than
the existing medicines is it easy to decide that it should be included
in the drug beneﬁt scheme. However, in most cases the price and
effectiveness are higher, and the cost of treatment must be weighed
against the value of the treatment. A high price requires evidence
for high value, which may  be difﬁcult to produce. The result, given
the present situation in Sweden, is that new drugs are introduced
slowly, to a small number of patients, and that not all patients who
could beneﬁt from a drug have access to it, at least initially.
The  second way  for patients to get access to cancer drugs is
through the county councils that pay for cancer care, including
drugs, at the hospitals. For drugs paid through hospital budgets
there is no formal process for assessment of cost-effectiveness;
which drugs to use is an administrative and clinical decision. In
many counties, the oncology clinic is responsible for all medications
used, including those that are prescribed and dispensed through
pharmacies, so there is basically no difference between the two
systems for cancer drugs from a payment and cost perspective. It is
also up to the oncology clinics whether they want to use drugs that
are recommended, or not recommended, by the TLV. There are a
number of examples of companies choosing to make an agreement
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ith the county instead of going to the TLV for oral cancer drugs.
ounty councils can also make non-public agreements with indi-
idual companies. The framework for these agreements is currently
nder discussion.
Having two different systems for making assessments and deci-
ions about reimbursement and use of cancer drugs is not rational.
n addition, both routes to public payment and use have pros and
ons, which need to be taken into account when designing a more
ptimal system.
The  TLV process includes only prescription drugs. Many cancer
rugs are given as injections or infusions, and are therefore, at least
t present, not assessed by the TLV (requisition drugs) even if they
re used in ambulatory care. A second problem is that the TLV in
rinciple grants subsidy for a particular product for a particular
ndication. Since value is dependent on the use, this changes with
ew indications. A third problem is that the price is ofﬁcial. This can
ffect the price the company can obtain in other countries, through
he system of international reference pricing.
There are also problems with the “county process”. First, it may
ead to undesirable regional differences. However, there is no doc-
mentation to show that the observed differences in overall access
o new cancer drugs lead to differences in health outcomes [26].
nother problem is that a decentralised solution would give small
ounties an unfavourable position in the negotiations. This problem
s limited as cancer care is concentrated into six HCRs and can be
vercome through cooperation between counties within an HCR. A
hird problem with a decentralised solution would be that ﬁnan-
ial aspects dominate decisions at local level. This is balanced by
he obligation of the county councils who are responsible both for
he costs and also for providing fair and effective care. The best
olution is therefore that the county councils negotiate both price
nd quantity, instead of ﬁrst determining the price at the central
evel and then quantities at the regional/local level.
egional versus national roles and responsibilities
The basic characteristic of the Swedish health-care system is the
esponsibility of the county council for the population‘s health, and
he authority of the county council to levy taxes to ﬁnance health
are. This means that it is the county council’s responsibility to
ake the trade-off between the objective of improved quality of
are and the resources and taxes that it entails. It is also the county
ouncil that is responsible for allocation of resources within the
ealth-care system.
This  leads us to the conclusion that the regional model, with
esponsibility of county councils/regions, is the one which should
e developed to adapt to the new developments in cancer care.
he regional cancer centres (RCCs), which are developed with sup-
ort from the government to coordinate cancer care at the regional
evel, also back this approach. However, it does require that the
ounty councils/regions build information systems and skills for
ffective decision-making and governance. It is also important that
he decision-making process will not be unnecessarily complicated,
ime-consuming and costly.
This  does not exclude the presence of national interests for the
mprovement of cancer care. National interests are expressed in
ational legislation and the decisions of the national authorities. If
e look speciﬁcally at cancer drugs, there are now a national cancer
trategy and a national pharmaceutical strategy in place. There are
lso national guidelines for treatment of various diseases, including
ancer, expressing demands for national standards. The guidelines
or the major tumour groups developed by the National Board for
ealth and Welfare are also important to achieve good and cost-
ffective cancer care. For support of this approach, see the recent
olicy review by the National Audit Ofﬁce [27].ancer Policy 2 (2014) 45–62 57
The way forward
This  review of cancer drug introductions in Sweden reveals a
need to improve the process. A key factor is to deﬁne the roles
of national and regional decision-making to make sure that they
are coordinated and support each other. A process is needed for
a national assessment of the cost-effectiveness of cancer drugs,
as with all new medical technologies. Cost-effectiveness is an
important criterion for the allocation of health-care resources.
Swedish health-care law also stipulates that this principle should
be followed. Therefore, there is a national interest in assessing
cost-effectiveness and in following up that the decisions made at
the county level are in line with the law. TLV has extensive expe-
rience in making assessments for prescription drugs and from a
pilot project for requisition drugs. It would be a natural exten-
sion to give the TLV this responsibility for all (cancer) drugs. We
see several advantages to this. The ﬁrst is that the responsibility
rests with an agency that is guided by legislation. Second, the TLV
has developed collaborations with Läkemedelsverket, the Swedish
Medical Products Agency, SBU the Swedish Council on Health Tech-
nology Assessment, and the National Board of Health and Welfare
responsible for national clinical guidelines. There is rationality in
cooperation and division of tasks by government agencies with
responsibilities in the same ﬁeld. The opportunities for engag-
ing the county councils in assessment of new drugs should be
explored.
One problem with the current mandate for the TLV is that deci-
sions on reimbursement are linked to a certain price. This link
to price control should be removed and replaced with free pri-
cing. The TLVs assessment and recommendations could instead,
like the recommendations by NICE, be based on a deﬁned price.
The recommendation could then be used by the county councils
for contracting for prescription drugs, in the same way as can be
done today for hospital drugs, including requisition drugs used for
ambulatory treatment. All cancer drugs should be handled in the
same way, regardless of whether they are consumed at home or at
the hospital clinic. The system in Canada for assessment of cancer
drugs, with a central review as a guide for decisions at the provincial
level is an example of how this can work (www.pCODR.ca).
There is no need for a central authority to negotiate prices for
new cancer drugs. Payments based on value should be the guiding
principle at the regional level. Since it is difﬁcult to determine the
value and use before the drug is studied in clinical practice, it is also
impossible to determine a price up front. On the basis of the health
economic evaluation, one can evaluate the cost-effectiveness based
on different indications/assumptions. It will be up to the county to
use this information when negotiating with companies and making
agreements about use, where price is one parameter.
If the price is determined at the central level, it must be linked
to the expected use – i.e. volume – for it to be meaningful. But the
TLV has no control of volumes for drugs that are either included or
excluded from the reimbursement scheme. As mentioned earlier,
there is a risk that the central price is set based on the most valu-
able indication. That will prevent use in other patient populations
until the patent expires. This could be avoided if pricing was  con-
structed as a two-part tariff, where those additional patients can be
treated at a heavily discounted price. It would encourage the use
within indications for which the value is lower or unclear. Such a
two-step tariff is common in the pricing of goods and services with
high ﬁxed costs and low marginal costs, and has been proposed for
the pharmaceutical sector in a paper by Person et al. [28]. It also
links to discussions on “patent acquisition” as a model for achiev-
ing both dynamic and static efﬁciency [29]. Practical examples are
few because of the difﬁculties of organising “buyers” and dividing
the costs between them [30]. The French model, with price–volume
agreements at the central level are combined with “free access” to
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he drug within the health-care system can be seen as an approxi-
ation of this approach.
Central  pricing requires a national budget for innovative drugs,
nd could be an option for an introductory period of 3–5 years.
hose drugs would thus be paid outside the normal county coun-
il budgets. But such a system needs to be carefully managed in
rder to provide the correct incentives for use of innovative drugs.
 system with regional responsibility for payments of innovative
ancer drugs, as is the case for all other resources needed for cancer
are, is most consistent with the regionalised health-care model in
weden.
ntroduction and monitoring of new cancer drugs at the regional
evel
The responsibility for using and monitoring the new cancer
rugs should, in our view, be on the county council/regional level,
ecause it gives the best opportunity to assess the beneﬁts for
atients and balance them against costs. The best opportunity to
ake an assessment of the costs and beneﬁts of a drug’s use for var-
ous indications is also at the regional level. The county council and
he managers and doctors who are responsible for cancer care must
lso be the ones responsible for collecting relevant data for mon-
toring clinical effectiveness. It is also on the regional level where
e ﬁnd the best skills to enter into agreements with pharmaceu-
ical companies. These agreements should be linked to treatment
utcome. There are many advantages to this – also for the pharma-
eutical industry. To be competitive, it is important to know what
he health-care system demands and is willing to pay for. Close con-
acts with providers and payers give information and incentives to
evelop products and services that suit medical needs.
The  two main goals of equal access to care and cost-effective use
f health-care resources must be monitored at the national level.
ata on use of treatments must be recorded at the individual patient
evel and compiled so that it is possible to analyse outcome and
able A1
ales  of cancer drugs in Sweden: 2011 sales after falling sales value.
Drug Sales (millions SEK) Per cent of total sales 
Trastuzumab 326 11.8 
Rituximab  309 11.1 
Imatinib  208 7.5 
Bevacizumab 147 5.3 
Leuprorelin 145 5.2 
Bortezomib 129 4.7 
Lenalidomide 110 4.0 
Pemetrexed 97 3.5 
Sunitinib  65 2.4 
Temozolomide 64 2.3 
Goserelin  61 2.2 
Methotrexate 59 2.1 
Erlotinib  51 1.8 
Doxorubicin 50 1.8 
Paclitaxel  50 1.8 
Cetuximab  49 1.8 
Capecitabin 47 1.7 
Buserelin  46 1.7 
Docetaxel  43 1.6 
Dasatinib  42 1.5 
Letrozol  40 1.4 
Anastrozol  33 1.2 
Bicalutamide 33 1.2 
Nilotinib  33 1.2 
Azacitidin  30 1.1 
Sorafenib  30 1.1 
Talidomide 23 0.8 
Everolimus  22 0.8 
Gemcitabine 21 0.8 
Yperite  analougues 20 0.7 ancer Policy 2 (2014) 45–62
value. Regional differences will continue to be present, but this is
not necessarily a problem if they are part of the search for optimal
treatment strategies. What is not acceptable is if differences per-
sist over time, without any explanation. Variations in treatment
practices and patient outcomes should be published and debated.
This will lead to improvements and differences will probably
decrease.
For regions/county councils responsible for the introduction of
new cancer drugs it is important to balance investments in innova-
tive drugs against other interventions designed to improve care for
cancer patients. New drugs may  prolong survival and possibly cure
some cancer patients. However, it is important that high-quality
cancer care should provide all patients with good care in all stages
of the disease. New drugs are a part of this process, but they must
be seen in relation to the overall aim of the health service and bring
added value to society at a reasonable cost.
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See Tables A1 and B1.
Cumulative sales (millions SEK) Per cent cumulative sales
326 11.8
635 22.9
843 30.4
990 35.7
1135 41.0
1264 45.6
1374 49.6
1471 53.1
1536 55.4
1600 57.8
1661 60.0
1720 62.1
1771 63.9
1821 65.7
1871 67.5
1920 69.3
1967 71.0
2013 72.6
2056 74.2
2097 75.7
2138 77.1
2171 78.4
2204 79.5
2237 80.7
2267 81.8
2298 82.9
2321 83.8
2343 84.5
2364 85.3
2384 86.0
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Table  A1 (Continued)
Drug Sales (millions SEK) Per cent of total sales Cumulative sales (millions SEK) Per cent cumulative sales
Epirubicin 20 0.7 2404 86.8
Oxaliplatin 20 0.7 2424 87.5
Panitumumab 18 0.7 2442 88.1
Geﬁtinib  17 0.6 2459 88.7
Carboplatin 17 0.6 2476 89.4
Fulvestrant 16 0.6 2492 89.9
Vinorelbin  14 0.5 2506 90.4
Anagrelide  14 0.5 2520 90.9
Cabazitaxel  13 0.5 2533 91.4
Exemestane 13 0.5 2546 91.9
Abiraterone 13 0.5 2559 92.3
Irinotecan  13 0.5 2572 92.8
Pazopanib  12 0.4 2584 93.2
Trabectedin 12 0.4 2595 93.7
Lapatinib  11 0.4 2607 94.1
Methylaminolevulinate 11 0.4 2617 94.5
Cytarabine  9 0.3 2627 94.8
Other  chemotherapy drugs 9 0.3 2635 95.1
Alemtuzumab 8 0.3 2644 95.4
Topotecan  8 0.3 2652 95.7
Etoposide  8 0.3 2660 96.0
Fluorouracil 8 0.3 2668 96.3
Fludarabine 7 0.3 2675 96.5
Cyclophosphamide 7 0.2 2682 96.8
Triptorelin  6 0.2 2688 97.0
Tamoxifen  6 0.2 2694 97.2
Hydroxycarbamide 6 0.2 2700 97.4
Ifosfamide  5 0.2 2704 97.6
Ipilimumab 4 0.2 2709 97.8
Eribulin  4 0.2 2713 97.9
Amsakrin  4 0.1 2716 98.0
Streptozotocin 3 0.1 2720 98.2
Vincristine  3 0.1 2723 98.3
Temsirolimus 3 0.1 2726 98.4
Mercaptopurine 3 0.1 2729 98.5
Clofarabine  3 0.1 2732 98.6
Estradiol  3 0.1 2735 98.7
Vinﬂunine  3 0.1 2738 98.8
Mitomycin  3 0.1 2740 98.9
Ofatumumab 2 0.1 2743 99.0
Cisplatin  2 0.1 2745 99.1
Asparaginase 2 0.1 2747 99.1
Daunorubicin 2 0.1 2749 99.2
Mitotan  2 0.1 2751 99.3
Mitoxantron 2 0.1 2752 99.3
Aminolevuline acid 2 0.1 2754 99.4
Cladribine  1 0.0 2755 99.4
Idarubicin  1 0.0 2757 99.5
Bleomycin  1 0.0 2758 99.5
Melphalan  1 0.0 2759 99.6
Medroxiprogesterone 1 0.0 2760 99.6
Flutamide  1 0.0 2761 99.7
Bexarotene 1 0.0 2763 99.7
Estramustine 1 0.0 2764 99.7
Procarbazine 1 0.0 2765 99.8
Dacarbazine 1 0.0 2766 99.8
Busulfan  1 0.0 2767 99.8
Trofosfamide 1 0.0 2767 99.9
Nelarabine 0 0.0 2768 99.9
Tretinoin  0 0.0 2768 99.9
Vinblastine 0 0.0 2768 99.9
Alkylating  agents 0 0.0 2769 99.9
Lomustine  0 0.0 2769 99.9
Megestrol  0 0.0 2769 99.9
Clorambucil 0 0.0 2770 100.0
Tioguanine  0 0.0 2770 100.0
Vindesine  0 0.0 2770 100.0
Toremifene  0 0.0 2770 100.0
Degarelix  0 0.0 2771 100.0
Raltitrexed  0 0.0 2771 100.0
Catumaxomab 0 0.0 2771 100.0
Dactinomycin 0 0.0 2771 100.0
Other  alkylating agents 0 0.0 2771 100.0
Other  cytotoxic drugs 0 0.0 2771 100.0
Pegaspargase 0 0.0 2771 100.0
Teniposide  0 0.0 2771 100.0
Treosulfan  0 0.0 2771 100.0
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Table B1
Sales  of cancer drugs in Sweden (ATC kod 1 + 2A + 2B + thalidomide + lenalidomide) 2011 distributed after the year of introduction.
Drug Year of introduction (ﬁrst sales) Sales (millions SEK) Cumulative Sales (millions SEK) Per cent cumulative sales
Abiraterone 2011 13 13 0.5
Eribulin  2011 4 17 0.6
Ipilimumab 2011 4 21 0.8
Cabazitaxel  2011 13 35 1.2
Catumaxomab 2011 0 35 1.3
Degarelix  2010 0 35 1.3
Estradiol  2010 3 38 1.4
Ofatumumab 2010 2 40 1.4
Pazopanib  2010 12 52 1.9
Vinﬂunine  2010 3 55 2.0
Aminolevuline acid 2009 2 56 2.0
Azacitidine  2009 30 87 3.1
Nelarabine  2009 0 87 3.2
Temsirolimus 2009 3 90 3.3
Everolimus  2008 22 112 4.0
Lenalidomide 2008 110 221 8.0
Panitumumab 2008 18 240 8.7
Thalidomide 2008 23 263 9.5
Trabectedin 2008 12 275 9.9
Treosulfan  2008 0 275 9.9
Cytotoxic  drugs 2007 0 275 9.9
Dasatinib  2007 42 316 11.4
Clofarabin  2007 3 319 11.5
Yperite  analougues 2007 20 340 12.3
Lapatinib  2007 11 351 12.7
Nilotinib  2007 33 384 13.9
Pegaspargas 2007 0 384 13.9
Trofosamid 2007 1 384 13.9
Other  Alkylating agents 2007 0 384 13.9
Raltitrexed  2006 0 384 13.9
Sorafenib  2006 30 415 15.0
Sunitinib  2006 65 480 17.3
Bevacizumab 2005 147 627 22.6
Bexaroten  2005 1 628 22.7
Erlotinib  2005 51 679 24.5
Geﬁtinib  2005 17 696 25.1
Other  cytotoxic drugs 2005 9 705 25.4
Bortezomib 2004 129 834 30.1
Cetuximab  2004 49 884 31.9
Fulvestrant  2004 16 900 32.5
Pemetrexed 2004 97 997 36.0
Alemtuzumab 2001 8 1006 36.3
Alkylating  agents 2001 0 1006 36.3
Anagrelide  2001 14 1020 36.8
Capecitabine 2001 47 1067 38.5
Imatinib  2001 208 1274 46.0
Methylaminolevulinate 2001 11 1285 46.4
Mitotane  2001 2 1287 46.4
Streptozotocin 2001 3 1290 46.6
Exemestane 2000 13 1303 47.0
Trastuzumab 2000 326 1629 58.8
Hydroxycarbamide 1999 6 1635 59.0
Oxaliplatin  1999 20 1654 59.7
Temozolomide 1999 64 1719 62.0
Irinotekan  1998 13 1732 62.5
Rituximab  1998 309 2040 73.6
Letrozole  1997 40 2080 75.1
Topotecan  1997 8 2089 75.4
Anastrozole 1996 33 2122 76.6
Bikalutamide 1996 33 2155 77.8
Docetaxel  1996 43 2198 79.3
Vinorelbin  1996 14 2212 79.8
Asparaginase 1995 2 2214 79.9
Fludarabine 1995 7 2221 80.2
Gemcitabine 1995 21 2242 80.9
Kladribine  1994 1 2244 81.0
Toremifene 1994 0 2244 81.0
Tretinoin  1994 0 2244 81.0
Flutamide  1993 1 2246 81.0
Paclitaxel  1993 50 2295 82.8
Idarubicin  1991 1 2297 82.9
Ifosfamide  1990 5 2301 83.0
Triptorelin  1990 6 2307 83.3
Buserelin  1988 46 2353 84.9
Epirubicin  1988 20 2373 85.6
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Table  B1 (Continued)
Drug Year of introduction (ﬁrst sales) Sales (millions SEK) Cumulative Sales (millions SEK) Per cent cumulative sales
Goserelin 1988 61 2434 87.8
Carboplatin  1987 17 2451 88.4
Leuprorelin 1987 145 2596 93.7
Mitoxantrone 1987 2 2597 93.7
Vindesine  1985 0 2598 93.7
Amsakrin  1983 4 2601 93.9
Mitomycin  1983 3 2604 94.0
Etoposide  1982 8 2612 94.3
Tioguanine  1981 0 2612 94.3
Cisplatin  1980 2 2614 94.4
Dacarbazine 1980 1 2615 94.4
Megestrol  1979 0 2616 94.4
Teniposide  1979 0 2616 94.4
Doxorubicin 1978 50 2666 96.2
Lomustine  1978 0 2666 96.2
Bleomycin  1977 1 2668 96.3
Busulfan  1977 1 2668 96.3
Cyclophosphamide 1977 7 2675 96.6
Cytarabine  1977 9 2685 96.9
Dactinomycin 1977 0 2685 96.9
Daunorubicin 1977 2 2687 97.0
Estramustine 1977 1 2688 97.0
Fluorouracil 1977 8 2696 97.3
Clorambucil 1977 0 2696 97.3
Medroxiprogesterone 1977 1 2697 97.3
Melfalan  1977 1 2698 97.4
Mercaptopurine 1977 3 2701 97.5
Methotrexate 1977 59 2760 99.6
Procarbazine 1977 1 2761 99.6
Tamoxifen  1977 6 2767 99.9
Vinblastine 1977 0 2767 99.9
Vincristine  1977 3 2771 100.0
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